Verastem (VSTM)
(Delayed Data from NSDQ)
$6.08 USD
-0.09 (-1.46%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.08 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VSTM 6.08 -0.09(-1.46%)
Will VSTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VSTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VSTM
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
VSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology to Report Q1 Earnings: What's in the Cards?
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Other News for VSTM
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | VSTM ...
Verastem Oncology gets FDA fast track status for cancer drug
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS ...
Verastem: The Market Is Ignoring The Progress
Verastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock News